Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases

US7732162B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Torsten Hoffman · Halle (Saale), DE
• Stephan Schilling · Halle (Saale), DE
• Andre Niestroj · Halle (Saale), DE
• Hans-Ulrich Demuth · Halle (Saale), DE
• Ulrich Heiser · Halle (Saale), DE
• Mirko Buchholz · Halle (Saale), DE

Key dates

• Filing date: Mar 14, 2007
• Grant date: Jun 8, 2010
• Expiry date: Dec 2, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.